Lurasidone uses and dosages in Spain: RETROLUR, a real-world retrospective analysis using artificial intelligence
Lurasidone reduced positive and negative symptoms frequencies with a favorable safety profile, while low discontinuation rates suggest efficacy-tolerability balance, patient satisfaction, and acceptability. Our data reflect that in Spain lurasidone is used at low doses, limiting its beneficial effects according to clinical trials results.
Authors
- F. Mora (ORCID: https://orcid.org/0000-0001-9516-8823)
- C. Roset
- Irene Gabarda-Inat
- Mariano de Iceta Ibáñez de Gauna (ORCID: https://orcid.org/0000-0002-9488-3486)
- Carlos Gómez Sánchez-Lafuente (ORCID: https://orcid.org/0000-0002-8333-9792)
- D. H. Cámpora Pérez (ORCID: https://orcid.org/0000-0001-8998-9975)
- Elena Alvárez‐Barón
- Antonio Cárdenas
Institutions
- Universidad Complutense de Madrid (ES)
- Hospital Regional Universitario de Málaga (ES)
- Hospital Universitario Son Espases (ES)
- Angelini Pharma (Italy) (IT)
- Hospital Universitario Infanta Sofía (ES)
- Hospital Universitario Infanta Leonor (ES)
- Universidad Europea de Madrid (ES)
Publication Details
- Journal
- Frontiers in Psychiatry
- Published
- 2025-02-05
- DOI
- https://doi.org/10.3389/fpsyt.2024.1506142
- Citations
- 2
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.94
Funders
- Angelini Pharma